Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026

Contributed by: Business Wire

Logo

Tags

Women

Other Health

Other Science

Radiology

Research

Other Technology

Artificial Intelligence

Oncology

Consumer

Genetics

Data Management

Stem Cells

Science

Technology

Managed Care

FDA

General Health

Biotechnology

Health

More Like This

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024

Business Wire associated0

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

(Graphic: Business Wire)

MammaPrint® Reimbursement Indication Extended in Belgium

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit